PepGen Inc. (PEPG)Healthcare | Biotechnology | Boston, United States | NasdaqGS
2.44 USD
+0.10
(4.274%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:11 a.m. EDT
PepGen Inc. represents a catastrophic failure of investment thesis, combining a collapsed business model with a toxic capital structure. The company has lost over 88% of its value over the last three years, driven by a brutal -92% drop last year following FDA regulatory setbacks. Fundamentally, the picture is dire: the company is burning cash aggressively with negative free cash flow of nearly $50 million, negative operating cash flow, and crushing returns on equity and assets. The balance sheet is a ticking time bomb, carrying $165 million in debt against only $132 million in cash, leaving no runway for operations without dilution or distress. Despite a lofty analyst target price of $10.25, this is a classic value trap where the market has correctly priced the insolvency risk. The recent news of a partial clinical hold and subsequent stock plunge confirms that the core product pipeline is under severe threat. With no dividend to provide income and a high short interest suggesting widespread skepticism, the only logical move is to stay far away. The options market reflects this fear perfectly, with traders piling into deep out-of-the-money puts to hedge against further ruin. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.088759 |
| AutoARIMA | 0.088760 |
| MSTL | 0.117829 |
| AutoTheta | 0.684397 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 2.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.326 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.361 |
| Market Cap | 168,772,896 |
| Forward P/E | -1.98 |
| Beta | 1.88 |
| Website | https://www.pepgen.com |
As of July 11, 2026, 4:11 a.m. EDT: Speculators are overwhelmingly positioned for downside protection, with massive open interest in out-of-the-money puts relative to calls. While there is some speculative volume in deep out-of-the-money calls, the dominant strategy involves buying cheap insurance at strikes significantly below the current price, indicating a consensus expectation of further decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.96774197 |
| Address1 | 321 Harrison Avenue |
| Address2 | 8th Floor |
| All Time High | 20.0 |
| All Time Low | 0.88 |
| Ask | 2.96 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,257,070 |
| Average Daily Volume3 Month | 903,342 |
| Average Volume | 903,342 |
| Average Volume10Days | 1,257,070 |
| Beta | 1.879 |
| Bid | 1.78 |
| Bid Size | 2 |
| Book Value | 1.937 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.44 |
| Current Ratio | 14.979 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.519 |
| Day Low | 2.28 |
| Debt To Equity | 12.361 |
| Display Name | PepGen |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -79,905,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.664 |
| Enterprise Value | 53,030,884 |
| Eps Current Year | -1.13571 |
| Eps Forward | -1.23 |
| Eps Trailing Twelve Months | -1.46 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6837 |
| Fifty Day Average Change | 0.7563001 |
| Fifty Day Average Change Percent | 0.44918934 |
| Fifty Two Week Change Percent | 96.7742 |
| Fifty Two Week High | 7.8 |
| Fifty Two Week High Change | -5.36 |
| Fifty Two Week High Change Percent | -0.6871795 |
| Fifty Two Week Low | 1.01 |
| Fifty Two Week Low Change | 1.4300001 |
| Fifty Two Week Low Change Percent | 1.4158417 |
| Fifty Two Week Range | 1.01 - 7.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,651,843,800,000 |
| Float Shares | 36,046,153 |
| Forward Eps | -1.23 |
| Forward P E | -1.9837399 |
| Free Cashflow | -49,811,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00234 |
| Held Percent Institutions | 0.88374 |
| Implied Shares Outstanding | 69,169,215 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts. |
| Long Name | PepGen Inc. |
| Market | us_market |
| Market Cap | 168,772,896 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1677986244 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -77,216,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 169,464,576 |
| Number Of Analyst Opinions | 8 |
| Open | 2.33 |
| Operating Cashflow | -77,131,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 797 0979 |
| Pre Market Change | 0.03999996 |
| Pre Market Change Percent | 1.6393427 |
| Pre Market Price | 2.48 |
| Pre Market Time | 1,784,031,905 |
| Previous Close | 2.34 |
| Price Eps Current Year | -2.1484358 |
| Price Hint | 4 |
| Price To Book | 1.2596799 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.759 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.1 |
| Regular Market Change Percent | 4.27351 |
| Regular Market Day High | 2.519 |
| Regular Market Day Low | 2.28 |
| Regular Market Day Range | 2.28 - 2.519 |
| Regular Market Open | 2.33 |
| Regular Market Previous Close | 2.34 |
| Regular Market Price | 2.44 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,357,761 |
| Return On Assets | -0.35793 |
| Return On Equity | -0.68398005 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 69,169,215 |
| Shares Percent Shares Out | 0.057800002 |
| Shares Short | 4,000,179 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,745,084 |
| Short Name | PepGen Inc. |
| Short Percent Of Float | 0.0817 |
| Short Ratio | 6.41 |
| Source Interval | 15 |
| State | MA |
| Symbol | PEPG |
| Target High Price | 20.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 10.25 |
| Target Median Price | 10.5 |
| Total Cash | 132,303,000 |
| Total Cash Per Share | 1.913 |
| Total Debt | 16,561,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.075875 |
| Two Hundred Day Average Change | -1.6358747 |
| Two Hundred Day Average Change Percent | -0.4013555 |
| Type Disp | Equity |
| Volume | 2,357,761 |
| Website | https://www.pepgen.com |
| Zip | 2,118 |